Noxopharm Announces Leadership Transition
Filed with ASX · · 3 pages · English
Earlier from Noxopharm
- Noxopharm DARRT-2 Cancer Trial Update
- Noxopharm In-Licenses Novel RNA Technology From Hudson Institute of Medical Research
- Licencing Deal Expands Noxopharm Drug Opportunities
- Retraction of Grant Announcement
- Noxopharm Awarded A$8.8M Aust Govt Grant for Sarcoma Trial
Later from Noxopharm
- Noxopharm Receives A$5.865M R & D Tax Rebate
- December 2021 Quarterly Activities Report and Appendix 4C
- Appendix 4D and Half Year 2022 Financial Report
- First Patient Treated in CEP-2 Sarcoma Trial
- Orphan Drug Designation Granted to Noxopharm by US FDA
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm